Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
- Blood Clotting
- cell therapy
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 234445
The parties agreed to amend the agreement to expedite the expansion of our Phase 4 trial of Andexxa. The original agreement was entered into to study the safety and efficacy of Andexxa as a reversal agent to edoxaban, in our Phase 3 and Phase 4 studies. The Licensee is responsible for the cost of conducting these clinical studies. Pursuant to our agreement with Licensor, Licensee is obligated to provide research, development and regulatory services and to manufacture and supply Andexxa.
AndexXa (andexanet alfa), an investigational drug, is a modified human Factor Xa molecule that acts as a decoy to target and sequester with high specificity both oral and injectable Factor Xa inhibitors in the blood. Once bound, the Factor Xa inhibitors are unable to bind to and inhibit native Factor Xa, thus potentially allowing for the restoration of normal hemostatic processes. AndexXa is the first compound being studied as an antidote for Factor Xa inhibitors that directly and specifically reverses anti-Factor Xa activity â€“ the anticoagulant mechanism of these agents.
Licensee is developing andexanet alfa, a U.S. Food and Drug Administration (FDA)-designated Breakthrough Therapy, for patients treated with a direct or indirect Factor Xa inhibitor when reversal of anticoagulation is needed, such as for life-threatening or uncontrolled bleeding or emergency surgery and urgent procedures.
IPSCIO Record ID: 79329
Pursuant to this agreement, we are obligated to provide certain research and development activities outside of Japan, provide clinical drug supply and related manufacturing services and to participate on various committees.
Andexanet alfa is a drug under investigation as a potential antidote for factor Xa inhibitors, a group of anticoagulant (antiâ€“blood clotting) drugs that includes rivaroxaban, apixaban and edoxaban.
IPSCIO Record ID: 225746
IPSCIO Record ID: 201028
Elocta is a medication for the treatment and prophylaxis of bleeding in people with hemophilia A. Efmoroctocog alfa is a recombinant human coagulation factor VIII, Fc fusion protein.